Prognostic factors in clinical stage I non–small cell lung cancer
K Suzuki, K Nagai, J Yoshida, E Moriyama… - The Annals of thoracic …, 1999 - Elsevier
K Suzuki, K Nagai, J Yoshida, E Moriyama, M Nishimura, K Takahashi, Y Nishiwaki
The Annals of thoracic surgery, 1999•ElsevierBackground. Management of patients with early-stage lung cancer but a poor prognosis is
controversial. Methods. Between January 1987 and December 1994, 365 patients with
clinical stage I disease underwent surgical resection at our hospital. Eight preoperative
clinical variables were entered into univariate and multivariate analyses to determine their
impacts on 5-year survival. Results. The 3-year and 5-year survival rates were 78.1% and
66.5%, respectively. In the multivariate analysis, clinical T2 status and preoperative high …
controversial. Methods. Between January 1987 and December 1994, 365 patients with
clinical stage I disease underwent surgical resection at our hospital. Eight preoperative
clinical variables were entered into univariate and multivariate analyses to determine their
impacts on 5-year survival. Results. The 3-year and 5-year survival rates were 78.1% and
66.5%, respectively. In the multivariate analysis, clinical T2 status and preoperative high …
Background
Management of patients with early-stage lung cancer but a poor prognosis is controversial.
Methods
Between January 1987 and December 1994, 365 patients with clinical stage I disease underwent surgical resection at our hospital. Eight preoperative clinical variables were entered into univariate and multivariate analyses to determine their impacts on 5-year survival.
Results
The 3-year and 5-year survival rates were 78.1% and 66.5%, respectively. In the multivariate analysis, clinical T2 status and preoperative high serum carcinoembryonic antigen levels were independent significant factors indicative of a poor prognosis (hazard ratio, 2.20 and 1.88, respectively). Patients with both of these factors had 3-year and 5-year survival rates of 65% and 38% (p < 0.001), and the risk of death for this subgroup was 4.14 times greater than that of the overall clinical stage I population.
Conclusions
A subgroup with clinical T2 disease and preoperative high serum carcinoembryonic antigen levels had a significantly poorer prognosis among patients with clinical stage I lung cancer. For this subgroup, a complete preoperative staging workup and multimodal therapy, especially induction chemotherapy, instead of surgical intervention alone could be beneficial.
Elsevier